Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II)-Reference-Cited by-同舟云学术

Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II)

Published:2024-05-20 Issue:4 Volume:49 Page:491-506
ISSN:0378-7966
Container-title:European Journal of Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Eur J Drug Metab Pharmacokinet

Author:

T’jollyn Huybrecht^ORCID,Venkatasubramanian Raja,Neyens Martine,Gopal Srihari,Russu Alberto,Nandy Partha,Perez-Ruixo Juan Jose,Ackaert Oliver

Funder

Janssen Research and Development

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13318-024-00899-z.pdf

Reference17 articles.

1. Morris MT, Tarpada SP. Long-acting injectable paliperidone palmitate: a review of efficacy and safety. Psychopharmacol Bull. 2017;47(2):42–52.

2. Blackwood C, Sanga P, Nuamah I, Keenan A, Singh A, Mathews M, et al. Patients’ preference for long-acting injectable versus oral antipsychotics in schizophrenia: results from the patient-reported medication preference questionnaire. Patient Prefer Adherence. 2020;14:1093–102.

3. Mace S, Chak O, Punny S, Sedough-Abbasian D, Vegad C, Taylor DM, et al. Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics. Ther Adv Psychopharmacol. 2019;9:2045125319860977.

4. Pietrini F, Albert U, Ballerini A, Calo P, Maina G, Pinna F, et al. The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia. Neuropsychiatr Dis Treat. 2019;15:1045–60.

5. Najarian D, Sanga P, Wang S, Lim P, Singh A, Robertson MJ, et al. A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia. Int J Neuropsychopharmacol. 2022;25(3):238–51.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I);European Journal of Drug Metabolism and Pharmacokinetics;2024-05-15